文献速递头颈外科

未经选择的鳞状与非鳞状头颈癌中的胚系基因检测

Germline Genetic Testing in Unselected Squamous and Non-Squamous Head and Neck Cancers.
PubMed 文献 · Laryngoscope · 2023-05-03

这项前瞻性队列研究在三个三级学术医学中心对200例未经选择的头颈癌患者进行84基因胚系测序,发现10.5%携带致病性胚系变异,其中95.2%不符合现行指南检测标准,仅1例因变异改变治疗,家族变异检测完成率4.8%。

要点

  • 未经选择头颈癌患者中致病性胚系变异检出率为10.5%。
  • 携带变异者中95.2%不符合现行指南的检测标准。
  • 仅1例因检出致病性胚系变异而改变治疗决策。

核心结论

  • 通用基因面板检测在10.5%的头颈癌患者中检出致病性胚系变异,几乎全部会被现行指南检测遗漏。
  • 21例患者中仅1例因致病性胚系变异改变治疗,表明头颈癌治疗决策尚未广泛依据胚系变异。

研究设计与样本

  • 前瞻性队列研究,在三个三级学术医学中心开展。
  • 纳入2018年4月至2020年3月在Mayo Clinic Cancer Centers接受诊疗的未经选择头颈癌患者200例。
  • 采用84基因筛查平台进行胚系测序。

主要发现

  • 200例患者中位年龄62.0岁(Q1,Q3:55,71),女性23.0%,白人/非西班牙裔89.0%,西班牙裔/拉丁裔5.0%,其他种族6%,预后IV期疾病42.0%。
  • 最常见亚部位为口咽(45.0%)和唾液腺(12.0%),最常见组织学为鳞状细胞癌(74.5%)。
  • 21例患者(10.5%)共携带22个致病性胚系变异,其中20例(95.2%)不符合现行指南检测标准。
  • 22个致病性胚系变异中,11个为高或中穿透力(最常见PMS2或HOXB13),11个为低穿透力或隐性(最常见MUTYH、WNR或RECQL4)。
  • 1例患者因检出的致病性胚系变异改变治疗,家族变异检测完成率为4.8%。

关键数值与推荐

  • 致病性胚系变异检出率:21/200例(10.5%)。
  • 不符合现行指南检测标准者:20/21例(95.2%)。
  • 家族变异检测完成率:4.8%。

临床怎么用

  • 作者指出,头颈癌治疗决策尚未广泛依据胚系变异,原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study describes the prevalence of pathogenic germline variants (PGVs) in head and neck cancer patients, the incremental yield compared to a guideline-based approach to genetic evaluation, and the uptake of family variant testing. STUDY DESIGN: Prospective cohort study. SETTING: Three tertiary academic medical centers. METHODS: Germline sequencing using an 84-gene screening platform among unselected head and neck cancer patients who received care at Mayo Clinic Cancer Centers between April 2018 and March 2020. RESULTS: Amongst 200 patients, the median age was 62.0 years (Q1, Q3: 55, 71), 23.0% were female, 89.0% white/non-Hispanic, 5.0% Hispanic/Latinx, 6% of another race, and 42.0% had prognostic stage IV disease. The most common subsites were the oropharyngeal (45.0%) and salivary glands (12.0%). The most common histology was squamous cell carcinoma (74.5%). Twenty-one patients (10.5%) had a total of 22 PGVs; 20 of the 21 patients (95.2%) did not meet criteria for testing by current guidelines. Regarding penetrance of the 22 PGVs, 11 were high or moderate (most common PMS2 or HOXB13), and 11 were low or recessive (most common MUTYH, WNR, or RECQL4). One patient had a change in care based on an identified PGV. Family variant testing was completed at a rate of 4.8%. CONCLUSIONS: Universal gene panel testing identified a PGV in 10.5% of head and neck cancer patients; almost all would have been missed by current guideline-based testing. One of 21 patients had a treatment change due to their PGV, indicating that head and neck cancer treatment decisions are not yet widely informed by germline alterations. LEVEL OF EVIDENCE: 3 Laryngoscope, 133:3378-3388, 2023.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Brake DA, Idler BM, Kunze KL, et al. Germline Genetic Testing in Unselected Squamous and Non-Squamous Head and Neck Cancers. Laryngoscope. 2023. PMID: 37132629. doi:10.1002/lary.30720

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。